PURE Bioscience (PURE)
(Delayed Data from OTC)
$0.07 USD
0.00 (0.00%)
Updated Sep 20, 2024 01:41 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for PURE Bioscience falls in the month of July.
All items in Millions except Per Share data.
7/31/2024 | 7/31/2023 | 7/31/2022 | 7/31/2021 | 7/31/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 1 | 3 | 2 | 4 |
Receivables | NA | 0 | 0 | 0 | 1 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 1 |
Other Current Assets | NA | 0 | 0 | 0 | 0 |
Total Current Assets | NA | 2 | 4 | 3 | 6 |
Net Property & Equipment | NA | 0 | 1 | 1 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 2 | 4 | 4 | 6 |
Liabilities & Shareholders Equity | 7/31/2024 | 7/31/2023 | 7/31/2022 | 7/31/2021 | 7/31/2020 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 0 | 0 | 1 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 1 | 1 | 1 | 2 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 1 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 2 | 1 | 1 | 2 |
Shareholders Equity | 7/31/2024 | 7/31/2023 | 7/31/2022 | 7/31/2021 | 7/31/2020 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 1 | 1 | 1 | 1 |
Capital Surplus | NA | 132 | 132 | 128 | 127 |
Retained Earnings | NA | -133 | -129 | -126 | -123 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 0 | 4 | 3 | 5 |
Total Liabilities & Shareholder's Equity | NA | 2 | 4 | 4 | 6 |
Total Common Equity | 0 | 0 | 4 | 3 | 5 |
Shares Outstanding | 111.80 | 111.80 | 88.00 | 87.20 | 87.00 |
Book Value Per Share | 0.00 | 0.00 | 0.04 | 0.04 | 0.06 |
Fiscal Year End for PURE Bioscience falls in the month of July.
All items in Millions except Per Share data.
7/31/2024 | 4/30/2024 | 1/31/2024 | 10/31/2023 | 7/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 1 | 1 | 2 | 1 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 0 | 0 | 0 | 0 |
Total Current Assets | NA | 1 | 1 | 2 | 2 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 1 | 1 | 2 | 2 |
Liabilities & Shareholders Equity | 7/31/2024 | 4/30/2024 | 1/31/2024 | 10/31/2023 | 7/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 1 | 0 | 1 | 0 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 1 | 1 | 1 | 1 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 2 | 2 | 2 | 1 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 3 | 2 | 3 | 2 |
Shareholders Equity | 7/31/2024 | 4/30/2024 | 1/31/2024 | 10/31/2023 | 7/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 1 | 1 | 1 | 1 |
Capital Surplus | NA | 133 | 133 | 132 | 132 |
Retained Earnings | NA | -136 | -135 | -134 | -133 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | -2 | -1 | 0 | 0 |
Total Liabilities & Shareholder's Equity | NA | 1 | 1 | 2 | 2 |
Total Common Equity | 0 | -2 | -1 | 0 | 0 |
Shares Outstanding | 111.80 | 111.80 | 111.80 | 111.80 | 111.80 |
Book Value Per Share | 0.00 | -0.02 | -0.01 | 0.00 | 0.00 |